Breast Cancer Clinical Trial

Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors

Summary

This randomized pilot clinical trial studies omega-3 fatty acid in reducing cancer-related fatigue in breast cancer survivors. Supplementation with omega-3 fatty acid may help reduce cancer-related fatigue in breast cancer survivors.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To collect preliminary statistical data (mean changes and standard deviations) on two omega-3 supplementation (omega-3 fatty acid) regimens (1.65 g/day and 3.3 g/day) compared to placebo for reducing cancer-related fatigue (CRF) in fatigued breast cancer survivors.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive low-dose omega-3 fatty acid supplementation orally (PO) twice daily (BID) and placebo PO BID for 6 weeks.

ARM II: Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.

ARM III: Patients receive placebo PO BID for 6 weeks.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Have a confirmed diagnosis of breast cancer; participants can have had more than one primary cancer diagnosis in the past
Have undergone some type or combination of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer
Have completed all forms of standard adjuvant treatment (surgery, chemotherapy, radiation therapy) for breast cancer between 4 and 36 months prior to enrollment in the study; participants can be currently taking hormones (such as tamoxifen) or monoclonal antibodies (such as Herceptin)
Must have cancer-related fatigue, as indicated by a response of 4 or greater when asked to rate their level of fatigue at its worst in the past week on an 11-point scale anchored by "0" = no fatigue and "10" = as bad as you can imagine
Be able to read English
Able to swallow medication
Give written informed consent

Exclusion Criteria:

Have used marine omega-3 supplements at any time within previous 3 months (this includes prescription omega-3 drugs such as Lovaza®)
Be taking anticoagulant medication (does not include aspirin)
Have sensitivity or allergy to fish and/or shellfish
Have sensitivity or allergy to soy and/or soybeans
Have confirmed diagnosis of chronic fatigue syndrome or other diagnosis known to cause severe fatigue

Study is for people with:

Breast Cancer

Estimated Enrollment:

108

Study ID:

NCT02352779

Recruitment Status:

Completed

Sponsor:

Gary Morrow

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Wichita NCORP
Wichita Kansas, 67214, United States
Cancer Research Consortium of West Michigan
Grand Rapids Michigan, 49503, United States
University of Rochester NCORP Research Base
Rochester New York, 14642, United States
Dayton NCORP
Dayton Ohio, 45420, United States
Greenville Health System NCORP
Greenville South Carolina, 29605, United States
Wisconsin NCORP
Marshfield Wisconsin, 54449, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

108

Study ID:

NCT02352779

Recruitment Status:

Completed

Sponsor:


Gary Morrow

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.